Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)

被引：63

作者：

Leonard, JP

Link, BK

机构：

[1] Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, New York, NY 10021 USA

[2] Cornell Univ, Weill Med Coll, Div Hematol Oncol, New York, NY 10021 USA

[3] New York Presbyterian Hosp, New York, NY USA

[4] Univ Iowa, Coll Med, Holden Comprehens Canc Ctr, Iowa City, IA USA

[5] Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA

来源：

关键词：

D O I：

10.1053/sonc.2002.30149

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：81 / 86

页数：6

共 50 条

[1] BAUM RP, 1994, CANCER, V73, P896, DOI 10.1002/1097-0142(19940201)73:3+<896::AID-CNCR2820731322>3.0.CO
[2] 2-H
[3] Coiffier B, 2000, BLOOD, V96, p223A
[4] HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor
Elasser, D
Valerius, T
Repp, R
Weiner, GJ
Deo, Y
Kalden, JR
vandeWinkel, JGJ
Stevenson, GT
Glennie, MJ
Gramatzki, M
[J]. BLOOD, 1996, 87 (09) : 3803 - 3812
[5] ENGEL P, 1993, J IMMUNOL, V150, P4719
[6] EPSTEIN AL, 1987, CANCER RES, V47, P830
[7] GINGRICH RD, 1990, BLOOD, V75, P2375
[8] Golay J, 2000, BLOOD, V95, P3900
[9] TARGETING, DOSIMETRY, AND RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMAS WITH IODINE-131-LABELED LL2 MONOCLONAL-ANTIBODY
GOLDENBERG, DM
HOROWITZ, JA
SHARKEY, RM
HALL, TC
MURTHY, S
GOLDENBERG, H
LEE, RE
STEIN, R
SIEGEL, JA
IZON, DO
BURGER, K
SWAYNE, LC
BELISLE, E
HANSEN, HJ
PINSKY, CM
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) : 548 - 564
[10] Green JM, 2000, BLOOD, V96, p133A